PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCL

Primary Objectives

• To determine the proportion of patients whose BostonGene Tumor Portrait Molecular Test results are available to the treating physician by the start of Cycle 2 of standard-ofcare anthracycline-based therapy

• Standard of Care (SOC) (Other): Standard of care

Primary outcomes

• Safety and adverse events (AEs) [Through study completion; an average of 1 year.]: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Sex: All, ages: 18 Years to any

Eligibility Criteria

* Age ≥18y
* Pathology-confirmed diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma (HGBL) who are eligible for standard-of-care, full-dose 6 cycles of anthracycline-based treatment
* Stage 3 or 4 disease by Lugano Criteria
* Available biopsy sample for BostonGene Tumor Portrait™ test ( for sample preparation)

Exclusion Criteria

* Known central nervous system (CNS) disease (cases concerning for CNS involvement should be evaluated with MRI and lumbar puncture)
* Any baseline characteristics that in the opinion of the treating physician would preclude patients from receiving standard-of-care anthracycline-based treatment
* Participation (or planning to participate) in any therapeutic clinical trials for lymphoma during the planned treatment course. Note, patients who become eligible for other studies based on inadequate response, toxicity to therapy, or other reasons that arise after the initiation of standard therapy on this study are permitted to pursue those alternative trials as appropriate. Participation in other non-therapeutic and/or observational studies are permitted.

• Dai Chihara, MD, Principal investigator, UT MD Anderson Cancer Center